Skip to main content

Table 1 Patient characteristics

From: Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

Characteristics number of patients (n = 19)
Gender Male 18, Female 1
Median age (range), years 67 (49–80)
Histology Squamous cell carcinoma 13
Adenocarcinoma 4
Adenosquamous cell carcinoma 1
Large cell carcinoma 1
Smoke history Current 6, Former 13
Pack-years (range) 45 pack-years(12.5–116)
Performance status PS0 1, PS1 18
Treatment line 2nd line, 6
3rd line, 8
More than 4th line, 5
PD-1/PD-L1 antibodies Nivolumab 18
Atezolizumab 1
Adverse events Interstitial pneumonia 10
diarrhea 2
hematological toxicity 2
anaphylactic 2, eruption 1,
hemoptysis 1, hypophysitis1
Treatment for adverse events Steroid 14, others 5